ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CPRX Catalyst Pharmaceuticals Inc

14.98
0.25 (1.70%)
Apr 24 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 942,143
Bid Price 14.92
Ask Price 15.45
News -
Day High 15.185

Low
11.09

52 Week Range

High
17.765

Day Low 14.73
Company Name Stock Ticker Symbol Market Type
Catalyst Pharmaceuticals Inc CPRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.25 1.70% 14.98 20:00:00
Open Price Low Price High Price Close Price Prev Close
14.80 14.73 15.185 15.12 14.73
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
13,221 942,143 $ 15.07 $ 14,200,236 - 11.09 - 17.765
Last Trade Time Type Quantity Stock Price Currency
19:59:09 28 $ 14.92 USD

Catalyst Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.78B 117.86M - 398.2M 71.41M 0.61 24.95
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Catalyst Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CPRX Message Board. Create One! See More Posts on CPRX Message Board See More Message Board Posts

Historical CPRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week15.7016.2514.7315.222,457,617-0.72-4.59%
1 Month15.9016.66514.7315.431,374,979-0.92-5.79%
3 Months14.7117.49513.116115.301,362,8840.271.84%
6 Months12.5617.49511.8914.741,412,4622.4219.27%
1 Year16.4317.76511.0914.001,474,749-1.45-8.83%
3 Years4.5822.114.4312.391,619,43610.40227.07%
5 Years5.4122.112.2358.661,771,5139.57176.89%

Catalyst Pharmaceuticals Description

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Your Recent History

Delayed Upgrade Clock